Sunday, 27 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Financial Results · Q4 FY26

Parmax Pharma Q4 FY26 Results: Net Loss of ₹0.6 Cr, Loss Narrows

Parmax Pharma Ltd reported revenue from operations of ₹3.3 Cr (-31.2% YoY) and a net loss of ₹0.6 Cr for Q4 FY26.

Q4 FY26 at a glance · ₹ crore
MetricQ4 FY26Q3 FY26Q4 FY25
Revenue from operations3.34.34.8
Other income0.00.0-0.1
Total income3.34.34.7
Profit before exceptional items & tax-2.3-0.7-0.7
Exceptional items0.00.01.1
Profit before tax-2.3-0.7-1.8
Net profit-0.6-0.7-1.5
Operating margin-69.7%-16.3%-38.3%

A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.

Growth
Revenue, year on year-31.20%
Source

BSE results filing, NSE: PARMAX. Figures extracted from the filing.

Read the filing ↗

Parmax Pharma Ltd: key numbers

Share price
₹136.40
Market cap
₹51.03 Cr
Revenue (annual)
₹12.11 Cr
Net profit (annual)
₹-4.16 Cr
P/E (TTM)
-42.7×Sector 50.4×
Promoter holding
64.66%+33.86% QoQ
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Parmax Pharma Ltd

All →
21:38 IST BSE
Other Announcement

Parmax Pharma Other Announcement

Parmax Pharma Ltd filed its quarterly shareholding pattern under Regulation 31. The disclosure reflects changes in promoter status following a previously concluded open offer.

20:52 IST BSE
Annual General Meeting

Parmax Pharma Annual General Meeting

Parmax Pharma Ltd will hold its 32nd Annual General Meeting on September 29, 2026. The meeting will address the adoption of financial statements and director appointments.

21:33 IST BSE
Capital Structure Change

Parmax Pharma Capital Structure Change

Parmax Pharma's promoters acquired shares via preferential allotment. This filing discloses the acquisition of equity stakes by eleven promoter-related entities.

Value
₹8.32 Cr
10:47 IST BSE
Capital Structure Change

Parmax Pharma Capital Structure Change

Promoter group members Dhiren Shah and Sunil Shah acquired 22,80,444 equity shares in Parmax Pharma Ltd. The acquisition occurred via a preferential allotment on August 29, 2026.